RESUMEN
The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new antipsychotic developed to overcome some of the limitations in the drug treatment of schizophrenia. It has been approved by regulating agencies for use in treatment of adult schizophrenia.
Asunto(s)
Adulto , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapéutico , Humanos , Isoxazoles/análogos & derivados , Isoxazoles/farmacocinética , Isoxazoles/uso terapéutico , Piperidinas/análogos & derivados , Piperidinas/farmacocinética , Piperidinas/uso terapéutico , Esquizofrenia/tratamiento farmacológicoRESUMEN
The aim of this study was to assess the effect and safety of leflunomide [LEF] in refractory RA and to review the literature on this subject. A one year prospective study was conducted on a group of patients [n: 15]. Mean duration of the disease was 6,46 years. Rheumatoid factor was present in 12 cases. Leflunomide was administered at a dos of 20mg/day following a loading dose of 100mg/day for three days. The efficacy of LEF was evaluated on clinical and biological parameters of RA evolutivity at one, 3,6,9 and 12 months. Our mean follow up period was about 8 months [2 to 12 months]. Good prognostic indicators of disease progression were observed with LEF at one month and later in eleven cases with a good safety. Non serious adverse events were observed with LEF. Our results confirm that LEF may present another therapeutic choice that is efficacious for the long term treatment of refractory RA. Nonetheless, these results must be evaluated on a larger series